Professor Gert Storm studied biology at the Utrecht University, The Netherlands. He graduated in 1983. He obtained his Ph.D. degree in 1987 at the Dept. of Pharmaceutics of the same university. His research interests are in the fields of biopharmaceutics and drug targeting. In 1988-1989 he was a visiting scientist at Liposome Technology Inc. in Menlo Park, USA, and visiting assistant professor at the School of Pharmacy, UCSF, San Francisco. In 1990-1991 he was senior research scientist at Pharma Bio-Research Consultancy B.V. in Zuidlaren, The Netherlands. During this period he contributed to the design, co-ordination and evaluation of clinical pharmacological studies. In September 1991 he took up his position at the Utrecht University. In 1999, he was appointed adjunct professor at the Royal School of Pharmacy, Copenhagen. From July 2009 on, he is Honorary Professor in Bio-macromolecular Drug Delivery at the University of Copenhagen. In 2000, he was appointed as professor (Targeted Drug Delivery) at Utrecht University. From 2012 on, he is also professor (Targeted Therapeutics) at the MIRA Institute of the University of Twente. Furthermore, he also keeps a position at the University Medical Center Utrecht (UMCU) within the CBOI institute (Center for Image-Guided Oncological Interventions), and is Visiting Professor at the Department of Pharmacy at the National University of Singapore.
He is author/co-author of about 500 original articles, reviews and book chapters, in the field of advanced drug delivery/drug targeting, and theme (co-)editor of Advanced Drug Delivery Reviews and the book ‘Long Circulating Liposomes. Old Drug, New Therapeutics’. Up to June 2016, his H-index is >75 (Google Scholar) and 66 (Scopus, cited in 17,000 publications). He is included in the 2014 and 2015 lists of The World’s Most Influential Scientific Minds of Thomson Reuters (Highly Cited Researchers, period 2002-2013). Also recognized in Europe as ‘Most Cited Author’ in the field of Pharmacology & Pharmacy (Publication Analysis 2005-2011, Labtimes 05/2013). He was co-ordinator of an Integrated Project (FP6) on targeted nanomedicines (MediTrans) based on the collaboration of 30 european partners and funded by the EC and industry. He is program director of the program Drug Delivery embedded within the recently approved New Nano Initiative (NanoNextNL) strongly sponsored by the dutch government and industry. He is also principal investigator of a national industry-academia partnership (HIFU-CHEM) studying the clinical application of MRI-guided high-intensity focused ultrasound (HIFU) to improve cancer chemotherapy with temperature-sensitive targeted nanomedicines. He is course director of the GUIDE/UIPS/LACDR Course on Advanced Drug Delivery & Drug Targeting, co-sponsored and accredited by EUFEPS and the GALENOS Network, and held in The Netherlands. He is on the Board of Scientific Advisors (BSA) of the Controlled Release Society (CRS). He is on the Scientific Board of the spin-off company Enceladus Pharmaceuticals BV (Amsterdam). He is involved in organizing conferences in the field of advanced drug delivery, e.g. Chairman of the ESF-UB Conference “Nanomedicine: Reality Now and Soon”, held 23-28 October 2010 in San Feliu de Guixols, Spain. He is member of the editorial (advisory) board of a variety of scientific journals. He was involved in the foundation and is currently on the board of the European Foundation for Clinical Nanomedicine (CLINAM) and The Netherlands Platform for Targeted Nanomedicine (NPTN). He has received awards for his activities as translational pharmaceutical scientist.
Contact: email@example.com or firstname.lastname@example.org